Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Margaret A Lindorfer

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Seminars in Hematology|July 24, 2018
Mechanisms of Complement-Mediated Damage in Hematological DisordersRonald P Taylor, Margaret A Lindorfer
Antibodies (Basel, Switzerland)|July 27, 2022
FcγR-Mediated Trogocytosis 2.0: Revisiting History Gives Rise to a Unifying HypothesisMargaret A Lindorfer, Ronald P Taylor
Current Protocols|October 13, 2023
Measurement of Trogocytosis: Quantitative Analyses Validated with Rigorous ControlsRonald P Taylor, Margaret A Lindorfer
Transplant International : Official Journal of the European Society for Organ Transplantation|July 24, 2009
Impact of low-dose rituximab on splenic B cells: evidence for the shaving reactionRonald P Taylor, Margaret A Lindorfer
Current Opinion in Immunology|July 1, 2008
Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodiesRonald P Taylor, Margaret A Lindorfer
Journal of Immunology Research|November 13, 2025
Inhibition of Complement Will Substantially Reduce the Anemia of MalariaRonald P Taylor, Margaret A Lindorfer
Blood|April 21, 2024
Antibody-drug conjugate adverse effects can be understood and addressed based on immune complex clearance mechanismsRonald P Taylor, Margaret A Lindorfer
Seminars in Hematology|March 31, 2010
Antigenic modulation and rituximab resistanceRonald P Taylor, Margaret A Lindorfer
Antibodies (Basel, Switzerland)|September 9, 2020
How Do mAbs Make Use of Complement to Kill Cancer Cells? The Role of Ca<sup>2</sup>Ronald P Taylor, Margaret A Lindorfer
Blood|December 16, 2014
Fcγ-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developmentsRonald P Taylor, Margaret A Lindorfer
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Seminars in Hematology|July 24, 2018
Mechanisms of Complement-Mediated Damage in Hematological DisordersRonald P Taylor, Margaret A Lindorfer
Antibodies (Basel, Switzerland)|July 27, 2022
FcγR-Mediated Trogocytosis 2.0: Revisiting History Gives Rise to a Unifying HypothesisMargaret A Lindorfer, Ronald P Taylor
Current Protocols|October 13, 2023
Measurement of Trogocytosis: Quantitative Analyses Validated with Rigorous ControlsRonald P Taylor, Margaret A Lindorfer
Transplant International : Official Journal of the European Society for Organ Transplantation|July 24, 2009
Impact of low-dose rituximab on splenic B cells: evidence for the shaving reactionRonald P Taylor, Margaret A Lindorfer
Current Opinion in Immunology|July 1, 2008
Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodiesRonald P Taylor, Margaret A Lindorfer
Journal of Immunology Research|November 13, 2025
Inhibition of Complement Will Substantially Reduce the Anemia of MalariaRonald P Taylor, Margaret A Lindorfer
Blood|April 21, 2024
Antibody-drug conjugate adverse effects can be understood and addressed based on immune complex clearance mechanismsRonald P Taylor, Margaret A Lindorfer
Seminars in Hematology|March 31, 2010
Antigenic modulation and rituximab resistanceRonald P Taylor, Margaret A Lindorfer
Antibodies (Basel, Switzerland)|September 9, 2020
How Do mAbs Make Use of Complement to Kill Cancer Cells? The Role of Ca<sup>2</sup>Ronald P Taylor, Margaret A Lindorfer
Blood|December 16, 2014
Fcγ-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developmentsRonald P Taylor, Margaret A Lindorfer
Pageof 7